Experimental study on defibrase in the treatment of rabbit bearing VX2 liver cancer

Objective: To investigate the inhibitory effect of batroxobin on the growth of VX2 liver cancer inrabbits. Methods: The model of rabbit bearing VX2 liver cancer was established by CT-guided transplant. Three weeks later, the rabbits bearing VX2 liver cancer successfully were randomized into study group (injection of batroxobin at a dose of 0.1 BU/kg via marginal ear veins of the rabbit) and the control group (injection of normal saline of the same volume via marginal ear veins of the rabbit). The change of FIB (fibrinogen) content in liver cancer of the study group was observed. The volume and growth rate of the liver cancer one day before and 28 days after batroxobin treatment were obseved and calculated. On the 28th day after batroxobin treatment, the rabbits were sacrificed and the number of metastatic nodules on pulmonary surface was recorded. Results: The content of FIB was not different between the two groups one day before the transplant or batroxobin treatment (P > 0.05). The contents of FIB in the study group on the 4th, 10th and 28th days after batroxobin treatment were significanly different from one day before batroxobin treatment (P < 0.05), but this effect was not observed in the control group (P > 0.05). Before batroxobin treatment, the volume of liver cancer in rabbit was not different between the two groups (P > 0.05), but it was increased on the 28th day after batroxobin treatment in both groups(P < 0.05), and the growth rate of the liver cancer in the study group was lower than that of the control group (P < 0.05). The metastatic lung lesions were observed in both groups, the metastatic rate was 100%. The mean numbers of the metastatic nodules on pulmonary surface in the study group and the control group were 73.8±8.8 and 87.8± 9.6, respectively (P < 0.05). Conclusion: Defibrase may inhibit the growth and metastasis of VX2 liver cancer in rabbit model. Copyright © 2013 by TUMOR.